The ablation of the USP32 gene led to a reduction in tumor development in a mouse xenograft study, suggesting that inhibition of USP32, which subsequently reduces PD-L1 protein levels, might be a viable therapeutic strategy for the treatment of CRC. Here, USP32 is linked to neoplasm.